Xultophy: combination therapy for the treatment of type 2 diabetes

Xultophy is the first product to combine a basal insulin and an incretin mimetic for the treatment of type 2 diabetes. Here Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Vinod Patel outlines its place in therapy.

Xultophy combination therapy for the treatment of type 2 diabetes

Add yours ↓
Web design and marketing agency Leamington Spa